292 related articles for article (PubMed ID: 36860862)
1. Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.
Schepisi G; Gianni C; Cursano MC; Gallà V; Menna C; Casadei C; Bleve S; Lolli C; Martinelli G; Rosti G; De Giorgi U
Front Immunol; 2023; 14():1118610. PubMed ID: 36860862
[TBL] [Abstract][Full Text] [Related]
2. The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors.
Evmorfopoulos K; Marsitopoulos K; Karachalios R; Karathanasis A; Dimitropoulos K; Tzortzis V; Zachos I; Vlachostergios PJ
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275869
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
Semaan A; Haddad FG; Eid R; Kourie HR; Nemr E
Future Oncol; 2019 Feb; 15(5):533-541. PubMed ID: 30624089
[TBL] [Abstract][Full Text] [Related]
4. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
Chen J; Jiang H
Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
[TBL] [Abstract][Full Text] [Related]
5. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
6. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
[TBL] [Abstract][Full Text] [Related]
7. Investigational targeted therapies for the treatment of testicular germ cell tumors.
Oing C; Kollmannsberger C; Oechsle K; Bokemeyer C
Expert Opin Investig Drugs; 2016 Sep; 25(9):1033-43. PubMed ID: 27286362
[TBL] [Abstract][Full Text] [Related]
8. The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer.
Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q
Med Oncol; 2022 Sep; 39(12):232. PubMed ID: 36175774
[TBL] [Abstract][Full Text] [Related]
9. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.
Winter C; Zengerling F; Busch J; Heinzelbecker J; Pfister D; Ruf C; Lackner J; Albers P; Kliesch S; Schmidt S; Bokemeyer C
World J Urol; 2022 Dec; 40(12):2863-2878. PubMed ID: 35554637
[TBL] [Abstract][Full Text] [Related]
10. New insights into germ cell tumor genomics.
Lafin JT; Bagrodia A; Woldu S; Amatruda JF
Andrology; 2019 Jul; 7(4):507-515. PubMed ID: 30896089
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab for the salvage treatment of desperate germ cell tumor: A case report.
Aksun MS; Ucgul E; Sahin TK; Guven DC; Aksoy S
J Oncol Pharm Pract; 2021 Sep; 27(6):1516-1519. PubMed ID: 33283628
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.
Soltantoyeh T; Akbari B; Karimi A; Mahmoodi Chalbatani G; Ghahri-Saremi N; Hadjati J; Hamblin MR; Mirzaei HR
Cells; 2021 Jun; 10(6):. PubMed ID: 34207884
[TBL] [Abstract][Full Text] [Related]
13. Immune mechanisms and possible immune therapy in testicular germ cell tumours.
Chovanec M; Mardiak J; Mego M
Andrology; 2019 Jul; 7(4):479-486. PubMed ID: 31169364
[TBL] [Abstract][Full Text] [Related]
14. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
Kozakova K; Mego M; Cheng L; Chovanec M
Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
[TBL] [Abstract][Full Text] [Related]
15. The Role of
Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Schepisi G; Casadei C; Toma I; Poti G; Iaia ML; Farolfi A; Conteduca V; Lolli C; Ravaglia G; Brighi N; Altavilla A; Martinelli G; De Giorgi U
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671294
[TBL] [Abstract][Full Text] [Related]
17. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy.
Yang K; Zhao Y; Sun G; Zhang X; Cao J; Shao M; Liang X; Wang L
Front Immunol; 2022; 13():1081546. PubMed ID: 36741400
[TBL] [Abstract][Full Text] [Related]
18. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
19. Poor prognosis of retroperitoneal mixed extragonadal germ cell tumors in an HIV-infected man with severe immunosuppression and bilateral cryptorchidism: a case report.
Li R; Li H
BMC Cancer; 2019 Mar; 19(1):244. PubMed ID: 30885154
[TBL] [Abstract][Full Text] [Related]
20. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
